Our Story
SL BIO Co., Ltd. (SL BIO) is developing next-generation solutions in immuno-oncology while actively expanding its established portfolio of cell-free biologic products. The company’s pipeline includes advanced cell-based immunotherapies alongside a commercially available exosome platform, positioning SL BIO at the intersection of clinical innovation and regenerative product delivery.
In 2024, the company completed a strategic capital raise and restructured its investment framework, supporting its continued growth across therapeutic and functional biologic sectors.
Innovation
SL BIO is innovating across two synergistic fronts: immuno-oncology and regenerative care. In cancer treatment, the company is advancing cell based technologies designed to improve clinical outcomes through the development of targeted immune cell therapies capable of identifying and eliminating tumor cells.
In parallel, SL BIO has established a exosome platform derived from plant and milk sources, which supports cosmetic and functional applications such as skin and scalp care. These cell-free biologics are formulated to promote regeneration, strengthen barrier function, and enhance overall skin vitality.
Together, these complementary innovations position SL BIO as a forward-thinking leader in both clinical-stage cancer immunotherapy and commercialized regenerative solutions.
Research & Development
SL BIO's research and development efforts center on advancing precision immunotherapy and regenerative biologics to improve patient outcomes. We focus on two main areas: cancer treatment and tissue support. In cancer therapy, SL BIO develops immune stem cells capable of targeting and destroying cancer cells, offering a more precise approach to treatment with the potential to reduce side effects.
For non-cellular regeneration, SL BIO has established a proprietary exosome platform derived from plant and milk sources. These naturally sourced, cell-free biologics are applied in skin and scalp care formulations to support renewal, hydration, and barrier integrity.
Through these dual R&D pathways, SL BIO continues to push the boundaries of immuno-oncology and regenerative care bringing forward innovative, accessible solutions.
Our Vision & Commitment
SL BIO’s vision is to revolutionize healthcare through cutting edge regenerative science, aiming to improve clinical outcomes with advanced cell-based and cell free platforms. Our commitment lies in harnessing the potential of immune stem cells for cancer immunotherapy and exosome technologies to address critical health challenges related to oncology, skin, and tissue health. By investing in these innovative modalities, SL BIO seeks to lead the way in personalized, precision care with a focus on healing, regeneration, and long-term quality of life.
Our dedication extends beyond technological development which means we are also committed to ongoing research, ethical collaboration, and responsible practices to ensure the safety, performance, and accessibility of our products. SL BIO’s mission is to bring transformative, science-backed therapies to the forefront enhancing lives and advancing global health through innovation.
